Short radiation plus chemo-immunotherapy before esophageal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell carcinoma that has not been treated before.
- Your cancer is at a stage where it can be removed with surgery (stage II or III).
- You are in good general health (able to care for yourself, with good organ function).
- You have not had radiation, chemotherapy, or surgery for this cancer, and you have no other active cancer.
- You do not have an autoimmune disease or a condition that weakens your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether combining two immunotherapy drugs (which boost your immune system to fight cancer) with a standard chemotherapy drug before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if this approach shrinks the tumor and helps you live longer.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.